| Document |
Document Title |
|
WO/2021/081677A1 |
Provided are compounds and salts having a structure of Formula (I) or (II): (I), and (II) wherein: both of the chiral carbon atoms denoted by "*" are both in the R configuration or both in the S configuration. Compounds and salts of Form...
|
|
WO/2021/082882A1 |
Disclosed is a method for anchoring and modifying a nano-drug on the surface of a living cell. The method comprises: introducing an active reaction group to the surface of a living cell by means of a hydrophobic tail chain of a cell memb...
|
|
WO/2021/004401A9 |
The present invention relates to a crystal form of a key intermediate of a BTK kinase inhibitor and a preparation method therefor, and belongs to the technical field of medicines. The crystal form is a (R)-1-(1-(tert-butyloxyl)pyrrolidin...
|
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
|
WO/2021/078073A1 |
Provided are an N-containing derivative of substituted phenol hydroxy acid ester, and the preparation and use thereof. A compound is represented by formula (I). A salt of the compound of formula (I) has good water solubility, and, in viv...
|
|
WO/2021/081141A1 |
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...
|
|
WO/2021/079380A1 |
The present invention relates to improved process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-
amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridi
n-3-yl)-5-oxopyrrolidine-2-carboxamide and...
|
|
WO/2021/079069A1 |
The present invention relates to novel energetic salts of formula C+A-, wherein: C+ is a cation derived from an amino acid; A- is an energetic nitrogen-containing anion chosen among the anions derived from dinitramide, trinitromethane (N...
|
|
WO/2021/080608A1 |
A tri-functional linker moiety: formula (I), where X and Y are linking chains, and its use for preparing dual-mechanistic drug conjugates, preferably in a site-specific manner.
|
|
WO/2021/078135A1 |
A pyrrole amide compound, a pharmaceutical composition thereof and use thereof. The compound or the pharmaceutical composition can be used as a mineralocorticoid receptor antagonist.
|
|
WO/2021/074392A1 |
The present invention relates to the field of oncology, laboratory tools and methods, and especially anti-tumor DNA crosslinking agents. Most patients with advanced solid tumors develop resistance to chemotherapy due to the ability of ca...
|
|
WO/2021/072487A1 |
The present disclosure relates generally to a class of sulfonamide-based compounds, compositions containing the same and the therapeutic use of the compounds in the treatment of cancer.
|
|
WO/2021/076890A1 |
Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.
|
|
WO/2021/069184A1 |
The present invention relates to a compound of formula (I), to the use thereof in electronic devices, to methods for producing said compound, and to electronic devices containing the compound.
|
|
WO/2021/067324A1 |
Disclosed herein are novel uses of ADMDP stereoisomers or their derivatives for the manufacture of a medicament for treating Pompe disease. Accordingly, the present disclosure provides a method of treating Pompe disease in a subject. The...
|
|
WO/2021/065483A1 |
A purification method in which an organic solvent, which has a boiling point exceeding 100°C at 1 atmosphere, is purified by being separated from a mixed solution of the organic solvent and water comprises: a step for passing the mixed ...
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/056647A1 |
The present application belongs to the technical fields of green catalysis and related chemistry, and discloses a catalyst for anti-Markovnikov hydroamination, a preparation method therefor and a use thereof. The catalyst consists of ato...
|
|
WO/2021/058754A1 |
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...
|
|
WO/2021/058002A1 |
Disclosed by the present application is a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring; specifically disclosed is the crystalline form of the compound of formula I; also comprised is a...
|
|
WO/2021/061701A1 |
The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic...
|
|
WO/2021/060517A1 |
The present invention provides a novel method for producing a derivative of an organic substance that contains one or more groups selected from the group consisting of a sulfanyl group, a selanyl group and a sulfino group. A method for p...
|
|
WO/2021/058024A1 |
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...
|
|
WO/2021/058001A1 |
Disclosed are a crystal form of a five-membered N heterocyclic compound, particularly, a crystal from of a compound as represented by formula I, and an application of the crystal form in preparation of a medication for preventing or trea...
|
|
WO/2021/056850A1 |
Provided are an eutectic crystal formed by apixaban and a carboxylic acid, and a preparation method therefor. The eutectic crystal comprises an apixaban/malonic acid eutectic crystal, an apixaban/D‐malate eutectic crystal, an apixaban/...
|
|
WO/2021/062168A1 |
Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeuti...
|
|
WO/2021/058021A1 |
A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug co...
|
|
WO/2021/055630A1 |
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...
|
|
WO/2021/055894A1 |
Methods of analyzing a drug polypeptide conjugate using tandem mass spectrometry involving dual tandem mass tags (TMTs) are described. Provided herein is an integrated method using TMTs to obtain three analytical measurements, termed "tr...
|
|
WO/2021/047528A1 |
The present invention relates to the technical field of medicine, and disclosed are maleate of a nicotinyl alcohol ether derivative, a crystal form thereof, and an application thereof, i.e., (S)-N-(2-(pyridine-3-methoxy)-4-(2-bromo-3-phe...
|
|
WO/2021/045153A1 |
Provided is a method for producing gamma-butyrolactone, said method including a reaction step in which a raw material composed of one or both of 2-hydroxytetrahydrofuran and 4-hydroxybutyraldehyde and a catalyst containing copper and an ...
|
|
WO/2021/046286A1 |
A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a me...
|
|
WO/2021/046290A1 |
A pharmaceutical composition for topical wound treatment comprising one or more nitrogenous heterocyclic compound of 5 or 6 atoms with imide group; one or more deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and one or mor...
|
|
WO/2021/041320A1 |
Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.
|
|
WO/2021/038490A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...
|
|
WO/2021/030554A1 |
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.
|
|
WO/2021/027813A1 |
The present invention relates to a method for preparing asenapine. Specifically, the present invention relates to a method for preparing a pharmaceutically acceptable asenapine free base and a crystal form thereof, as well as a method fo...
|
|
WO/2021/026047A1 |
The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or p...
|
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/026465A1 |
Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2021/023818A1 |
The present invention relates to the field of flavor. More particularly, it concerns a precursor compound of formula (I) releasing 2-acetyl- 1-pyrroline and and a method to release 2-acetyl- 1-pyrroline from the precursor compound of for...
|
|
WO/2021/021629A1 |
The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/017904A1 |
Provided are fluorescent nanoparticles and their conjugates and methods of using the same for in vivo and in vitro diagnostics and other applications. In some embodiments, provided are fluorescent nanoparticles with high solid-state abso...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2021/010681A2 |
The present invention provides a method for preparing a (3R,5R)-7-(2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-((4-hydr
oxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt. The preparation method of th...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/006598A1 |
The present invention relates to a method for purifying a waste N-methyl-2-pyrrolidone (hereinafter referred to as NMP) mixture solution and, more specifically, to a method for purifying a waster NMP mixture solution by using a base. Acc...
|
|
WO/2020/264490A1 |
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or ly...
|
